Vai trò tiên lượng của dấu ấn sinh học sST2 trong suy tim - 19

TÀI LIỆU THAM KHẢO

Tiếng Việt

1. Nguyễn Ngọc Thanh Vân, Châu Ngọc Hoa. Tổng quan quản lý suy tim. Tạp chí Y Học Thành phố Hồ Chí Minh. 2019;23(2):1-3.

2. Spencer L James, Degu Abate, Kalkidan Hassen Abate, Solomon M Abay, Cristiana Abbafati. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. Nov 10 2018;392(10159):1789-1858. doi:10.1016/s0140-6736(18)32279-7

3. Špinar J, Špinarová L, Vítovec J. Pathophysiology, causes and epidemiology of chronic heart failure. Vnitr Lek. Fall 2018;64(9):834-838. Patofyziologie, příčiny a epidemiologie chronického srdečního selhání.

4. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. Journal of the American College of Cardiology. Apr 1 2014;63(12):1123-1133. doi:10.1016/j.jacc.2013.11.053

5. Pillai HS, Ganapathi S. Heart failure in South Asia. Current cardiology reviews. May 2013;9(2):102-11. doi:10.2174/1573403x11309020003

6. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circulation journal : official journal of the Japanese Circulation Society. 2013;77(9):2209-17. doi:10.1253/circj.cj-13-0971

Có thể bạn quan tâm!

Xem toàn bộ 193 trang tài liệu này.

7. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. Journal of the American College of Cardiology. Jan 29 2013;61(4):391-403. doi:10.1016/j.jacc.2012.09.038

8. Krumholz HM, Merrill AR, Schone EM, et al. Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circulation Cardiovascular quality and outcomes. Sep 2009;2(5):407- 13. doi:10.1161/circoutcomes.109.883256

9. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. The New England journal of medicine. Dec 23 1971;285(26):1441-6. doi:10.1056/nejm197112232852601

10. Taylor CJ, Ryan R, Nichols L, Gale N, Hobbs FR, Marshall T. Survival following a diagnosis of heart failure in primary care. Fam Pract. Apr 1 2017;34(2):161-168. doi:10.1093/fampra/cmw145

11. Lam CSP. Heart failure in Southeast Asia: facts and numbers. ESC Heart Fail. Jun 2015;2(2):46-49. doi:10.1002/ehf2.12036

12. Reyes EB, Ha JW, Firdaus I, et al. Heart failure across Asia: Same healthcare burden but differences in organization of care. International journal of cardiology. Nov 15 2016;223:163-167. doi:10.1016/j.ijcard.2016.07.256

13. Orso F, Fabbri G, Maggioni AP. Epidemiology of Heart Failure. Handb Exp Pharmacol. 2017;243:15-33. doi:10.1007/164_2016_74

14. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European heart journal. Jul 2012;33(14):1787-847. doi:10.1093/eurheartj/ehs104

15. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. Oct 15 2013;62(16):e147-239. doi:10.1016/j.jacc.2013.05.019

16. Phạm Nguyễn Vinh, Nguyễn Lân Việt, Đặng Vạn Phước. Khuyến cáo về chẩn đoán và điều trị suy tim của Hội Tim mạch học quốc gia Việt Nam 2015. Hội Tim mạch học Việt Nam; 2015.

17. Gupta DK, Wang TJ. Natriuretic Peptides and Cardiometabolic Health. Circulation journal : official journal of the Japanese Circulation Society. 2015;79(8):1647-55. doi:10.1253/circj.CJ-15-0589

18. Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European journal of heart failure. Jun 2019;21(6):715-731. doi:10.1002/ejhf.1494

19. Baba M, Yoshida K, Ieda M. Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation. Int J Mol Sci. Jun 10 2019;20(11)doi:10.3390/ijms20112824

20. Cowie MR, Lopatin YM, Saldarriaga C, et al. The Optimize Heart Failure Care Program: Initial lessons from global implementation. International journal of cardiology. Jun 1 2017;236:340-344. doi:10.1016/j.ijcard.2017.02.033

21. Gaggin HK, Januzzi JL, Jr. Natriuretic peptides in heart failure and acute coronary syndrome. Clinics in laboratory medicine. Mar 2014;34(1):43-58, vi. doi:10.1016/j.cll.2013.11.007

22. Gonseth J, Guallar-Castillón P, Banegas JR, Rodríguez-Artalejo F. The effectiveness of disease management programmes in reducing hospital re-admission in older patients with heart failure: a systematic review and meta-analysis of

published reports. European heart journal. Sep 2004;25(18):1570-95. doi:10.1016/j.ehj.2004.04.022

23. Krumholz HM, Amatruda J, Smith GL, et al. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. Journal of the American College of Cardiology. Jan 2 2002;39(1):83-9. doi:10.1016/s0735- 1097(01)01699-0

24. Lainscak M, Cleland JG, Lenzen MJ, et al. Recall of lifestyle advice in patients recently hospitalised with heart failure: a EuroHeart Failure Survey analysis. European journal of heart failure. Nov 2007;9(11):1095-103. doi:10.1016/j.ejheart.2007.08.001

25. Sarhene M, Wang Y, Wei J, et al. Biomarkers in heart failure: the past, current and future. Heart Fail Rev. Nov 2019;24(6):867-903. doi:10.1007/s10741-019- 09807-z

26. Miller WL, Saenger AK, Grill DE, Slusser JP, Bayes-Genis A, Jaffe AS. Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure. J Card Fail. Apr 2016;22(4):249-55. doi:10.1016/j.cardfail.2015.07.017

27. Felker GM, Fiuzat M, Shaw LK, et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail. Jan 2012;5(1):72- 8. doi:10.1161/circheartfailure.111.963637

28. Gullestad L, Ueland T, Kjekshus J, et al. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J. Dec 2012;164(6):878-83. doi:10.1016/j.ahj.2012.08.021

29. McCarthy CP, Januzzi JL, Jr. Soluble ST2 in Heart Failure. Heart Fail Clin. Jan 2018;14(1):41-48. doi:10.1016/j.hfc.2017.08.005

30. O'Meara E, Prescott MF, Claggett B, et al. Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. May 2018;11(5):e004446. doi:10.1161/circheartfailure.117.004446

31. Daniels LB, Clopton P, Iqbal N, Tran K, Maisel AS. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am Heart J. Oct 2010;160(4):721-8. doi:10.1016/j.ahj.2010.06.033

32. Gaggin HK, Szymonifka J, Bhardwaj A, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart failure. Feb 2014;2(1):65-72. doi:10.1016/j.jchf.2013.10.005

33. Sobczak S, Wojtczak-Soska K, Ciurus T, Sakowicz A, Pietrucha T, Lelonek

M. Single sST2 protein measurement predicts adverse outcomes at 1-year follow-up in patients with chronic heart failure. Pol Arch Med Wewn. 2014;124(9):452-8. doi:10.20452/pamw.2403

34. Wojtczak-Soska K, Sakowicz A, Pietrucha T, Lelonek M. Soluble ST2 protein in the short-term prognosis after hospitalisation in chronic systolic heart failure. Kardiol Pol. 2014;72(8):725-34. doi:10.5603/KP.a2014.0085

35. Yao HC, Li XY, Han QF, et al. Elevated serum soluble ST2 levels may predict the fatal outcomes in patients with chronic heart failure. International journal of cardiology. 2015;186:303-4. doi:10.1016/j.ijcard.2015.03.269

36. Zhang R, Zhang Y, Zhang J, et al. Predict value of soluble ST2 on one-year mortality for hospitalized patients with chronic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi. Sep 2014;42(9):726-30.

37. Lê Ngọc Hùng, Lê Ngọc Ánh, Thái Trúc Linh, Lương Thị Hồng Gấm, Lê Tự Ngọc Sơn. Khảo sát khoảng tham chiếu của xét nghiệm sST2 trên huyết thanh người Việt Nam bình thường. Tạp chí Y Học Thành phố Hồ Chí Minh. 2016;20(1):208-219.

38. Vương Anh Tuấn, Lê Thanh Liêm. Vai trò của dấu ấn sinh học sST2 trong chẩn đoán khó thở do suy tim cấp. Tạp chí Y Học Thành phố Hồ Chí Minh. 2016;20(2):203-211.

39. Bozkurt B, Coats AJ, Tsutsui H, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. Mar 1 2021;doi:10.1016/j.cardfail.2021.01.022

40. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European heart journal. Sep 21 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368

41. Lương Ngọc Khuê, Phạm Mạnh Hùng, Nguyễn Lân Việt, et al. Hướng dẫn chẩn đoán và điều trị suy tim mạn tính. Quyết định số 1762/QĐ-BYT 2020.

42. Châu Ngọc Hoa. Dịch tễ học suy tim. Suy tim trong thực hành lâm sàng. 2014:1-12.

43. Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics- 2020 Update: A Report From the American Heart Association. Circulation. Mar 3 2020;141(9):e139-e596. doi:10.1161/cir.0000000000000757

44. López-Sendón J. The heart failure epidemic. Medicographia. 2011;33:363- 369

45. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. European journal of heart failure. Aug 2020;22(8):1342-1356. doi:10.1002/ejhf.1858

46. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. European heart journal. Mar 1999;20(6):447-55.

47. Redfield MM, Jacobsen SJ, Burnett JC, Jr., Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. Jama. Jan 8 2003;289(2):194-202. doi:10.1001/jama.289.2.194

48. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. Journal of the American College of Cardiology. Aug 1992;20(2):301-6. doi:10.1016/0735-1097(92)90094-4

49. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. Jan 26 2016;133(4):e38-360. doi:10.1161/cir.0000000000000350

50. Taylor CJ, Roalfe AK, Iles R, Hobbs FD. Ten-year prognosis of heart failure in the community: follow-up data from the Echocardiographic Heart of England Screening (ECHOES) study. European journal of heart failure. Feb 2012;14(2):176-

84. doi:10.1093/eurjhf/hfr170

51. Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population: The Rotterdam Study. European heart journal. Aug 2001;22(15):1318-27. doi:10.1053/euhj.2000.2533

52. Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. European journal of heart failure. Nov 2019;21(11):1306-1325. doi:10.1002/ejhf.1594

53. Trương Phi Hùng, Trương Quang Bình. Cơ chế sinh lý bệnh suy tim. Suy tim trong thực hành lâm sàng. 2014:15-27.

54. Hasenfuss G, Mann DL. Pathophysiology of Heart Failure. Braunwald Heart Disease 11th. 2018:442-460.

55. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. Journal of the American College of Cardiology. Jul 1992;20(1):248-54. doi:10.1016/0735-1097(92)90167-l

56. Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. Sep-Oct 2012;21(5):365-71. doi:10.1016/j.carpath.2011.11.007

57. Mann DL. Mechanisms and models in heart failure: A combinatorial approach. Circulation. Aug 31 1999;100(9):999-1008. doi:10.1161/01.cir.100.9.999

58. Januzzi JJL, Mann DL. Approach to the Patient with Heart Failure.

Braunwald's Heart Disease: A Textbook of Cardio. 2018:403-417.

59. Oudejans I, Mosterd A, Bloemen JA, et al. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. European journal of heart failure. May 2011;13(5):518-27. doi:10.1093/eurjhf/hfr021

60. Kelder JC, Cramer MJ, van Wijngaarden J, et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. Dec 20 2011;124(25):2865-73. doi:10.1161/circulationaha.111.019216

61. Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. Efficiently screening heart failure in patients with type 2 diabetes. European journal of heart failure. Feb 2015;17(2):187-95. doi:10.1002/ejhf.216

62. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. European journal of heart failure. Feb 2009;11(2):130-9. doi:10.1093/eurjhf/hfn013

63. Daniels LB, Clopton P, Bhalla V, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J. May 2006;151(5):999- 1005. doi:10.1016/j.ahj.2005.10.011

64. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal. Jul 14 2016;37(27):2129- 2200. doi:10.1093/eurheartj/ehw128

65. Mann DL. Management of Heart Failure Patients with Reduced Ejection Fraction. Braunwald's Heart Disease: A Textbook of Cardio. 2018:490-516.

66. Butler J, Fonarow GC, Zile MR, et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart failure. Apr 2014;2(2):97-112. doi:10.1016/j.jchf.2013.10.006

67. Januzzi Jr.James L., Mann DL. Clinical Assessment of Heart Failure.

Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 2014:473-483.

68. Kjeldsen SE, von Lueder TG, Smiseth OA, et al. Medical Therapies for Heart Failure With Preserved Ejection Fraction. Hypertension. Jan 2020;75(1):23-32. doi:10.1161/hypertensionaha.119.14057

69. Martin N, Manoharan K, Davies C, Lumbers RT. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev. May 22 2021;5(5):Cd012721. doi:10.1002/14651858.CD012721.pub3

70. Mc Causland FR, Lefkowitz MP, Claggett B, et al. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation. Sep 29 2020;142(13):1236-1245. doi:10.1161/circulationaha.120.047643

71. Silverman DN, Plante TB, Infeld M, et al. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial. JAMA Netw Open. Dec 2 2019;2(12):e1916598. doi:10.1001/jamanetworkopen.2019.16598

72. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England journal of medicine. Oct 14 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038

73. Felker GM, Teerlink JR. Diagnosis and Management of Acute Heart Failure.

Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 2018:462-488.

74. Mamas MA, Sperrin M, Watson MC, et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. European journal of heart failure. Sep 2017;19(9):1095-1104. doi:10.1002/ejhf.822

75. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. European journal of heart failure. Jun 2001;3(3):315-22. doi:10.1016/s1388- 9842(00)00141-0

76. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart (British Cardiac Society). Sep 2007;93(9):1137-46. doi:10.1136/hrt.2003.025270

77. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study. European heart journal. Mar 1999;20(6):421-8. doi:10.1053/euhj.1998.1280

78. Shah KS, Xu H, Matsouaka RA, et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. Journal of the American College of Cardiology. Nov 14 2017;70(20):2476-2486. doi:10.1016/j.jacc.2017.08.074

79. Dunlay SM, Redfield MM, Weston SA, et al. Hospitalizations after heart failure diagnosis a community perspective. Journal of the American College of Cardiology. Oct 27 2009;54(18):1695-702. doi:10.1016/j.jacc.2009.08.019

80. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. Sep 25 2007;116(13):1482-7. doi:10.1161/circulationaha.107.696906

81. Koudstaal S, Pujades-Rodriguez M, Denaxas S, et al. Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a

population-based linked electronic health record cohort study in 2.1 million people.

European journal of heart failure. Sep 2017;19(9):1119-1127. doi:10.1002/ejhf.709

82. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-- 2013 update: a report from the American Heart Association. Circulation. Jan 1 2013;127(1):e6-e245. doi:10.1161/CIR.0b013e31828124ad

83. Đỗ Thị Nam Phương, Nguyễn Anh Duy Tùng. Khảo sát các yếu tố tiên lượng tử vong trên bệnh nhân suy tim phân suất tống máu giảm nhập viện tại Viện tim TP.HCM. Chuyên đề Tim Mạch học. 2019;

84. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. Dec 10 2002;106(24):3068-72. doi:10.1161/01.cir.0000039105.49749.6f

85. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The New England journal of medicine. Aug 1 1991;325(5):293-302. doi:10.1056/nejm199108013250501

86. Trần Thị Ngọc Mỹ, Châu Ngọc Hoa. Đái tháo đường típ 2 ở bệnh nhân suy tim với phân suất tống máu giảm. Tạp chí Y Học Thành phố Hồ Chí Minh. 2019;23(1):203-208.

87. Nguyễn Hồng Thoại, Trần Kim Trang. Thiếu sắt ở bệnh nhân suy tim mạn.

Tạp chí Y Học Thành phố Hồ Chí Minh. 2019;23(1):221-225.

88. Drozd M, Relton SD, Walker AMN, et al. Association of heart failure and its comorbidities with loss of life expectancy. Heart (British Cardiac Society). Sep 2021;107(17):1417-1421. doi:10.1136/heartjnl-2020-317833

89. Baldi I, Azzolina D, Berchialla P, Gregori D, Scotti L, Corrao G. Comorbidity- adjusted relative survival in newly hospitalized heart failure patients: A population- based study. International journal of cardiology. Sep 15 2017;243:385-388. doi:10.1016/j.ijcard.2017.05.080

90. Pavlović A, Polovina M, Ristić A, et al. Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction. Eur J Prev Cardiol. Jan 2019;26(1):72- 82. doi:10.1177/2047487318807767

91. Dinatolo E, Dasseni N, Metra M, Lombardi C, von Haehling S. Iron deficiency in heart failure. J Cardiovasc Med (Hagerstown). Dec 2018;19(12):706-716. doi:10.2459/jcm.0000000000000686

92. Iorio A, Senni M, Barbati G, et al. Prevalence and prognostic impact of non- cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. European journal of heart failure. Sep 2018;20(9):1257-1266. doi:10.1002/ejhf.1202

..... Xem trang tiếp theo?
⇦ Trang trước - Trang tiếp theo ⇨

Xem tất cả 193 trang.

Ngày đăng: 12/05/2024